These results show that semaglutide may minimize these risk factors, thereby preventing kidney disease in people living with overweight or obesity
Course Highlights Discover how combining lifestyle modifications with GLP-1 receptor agonists can improve weight loss, glycemic control, and overall cardiometabolic health Examine the science behind GLP-1 receptor agonists, from their effects on insulin secretion and appetite regulation to next-generation agents like tirzepatide and orforglipron Learn best practices for patient education, dosing strategies, and interprofessional collaboration while addressing contraindications, adverse effects, and compounding warnings Introduction Obesity is a chronic and prevalent condition that impacts health, contributing to higher rates of morbidity and mortality
Obviously, this is all subject to individual sensitivities, proclivities, and situations
Our Process: Personalized Medical Weight Loss We make weight loss simple, supportive, and customized to your needs
Mounjaro is the brand name for tirzepatide, a novel medication that targets both GLP-1 and GIP receptors